| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Miguel A Boarati, Yuan-Pang Wang, Ana Paula Ferreira-Maia, Ana Rosa S Cavalcanti, Lee Fu-. Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder. The primary care companion for CNS disorders. vol 15. issue 3. 2013-10-30. PMID:24171144. |
six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder. |
2013-10-30 |
2023-08-12 |
Not clear |
| Miguel A Boarati, Yuan-Pang Wang, Ana Paula Ferreira-Maia, Ana Rosa S Cavalcanti, Lee Fu-. Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder. The primary care companion for CNS disorders. vol 15. issue 3. 2013-10-30. PMID:24171144. |
recent studies suggest that risperidone long-acting injection (rlai) may be considered for controlling mood episodes in bipolar disorder patients who have relapsed due to medication nonadherence or failure to respond to standard therapies. |
2013-10-30 |
2023-08-12 |
Not clear |
| J S Seo, K Jamieson, V Cosgrove, I S Gwizdowski, H Yang, D V Sheehan, S L McElroy, T Suppe. Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder. European psychiatry : the journal of the Association of European Psychiatrists. vol 28. issue 3. 2013-09-06. PMID:22130178. |
characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder. |
2013-09-06 |
2023-08-12 |
Not clear |
| Keming Gao, Mary Mackle, Pilar Cazorla, Jun Zhao, Armin Szeged. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatric disease and treatment. vol 9. 2013-09-04. PMID:24003306. |
comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. |
2013-09-04 |
2023-08-12 |
Not clear |
| Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, Ayal Schaffer, Serge Beaulieu, Martin Alda, Claire O'Donovan, Glenda Macqueen, Roger S McIntyre, Verinder Sharma, Arun Ravindran, L Trevor Young, Roumen Milev, David J Bond, Benicio N Frey, Benjamin I Goldstein, Beny Lafer, Boris Birmaher, Kyooseob Ha, Willem A Nolen, Michael Ber. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar disorders. vol 15. issue 1. 2013-08-12. PMID:23237061. |
lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone long-acting injection, and adjunctive ziprasidone continue to be first-line options for maintenance treatment of bipolar disorder. |
2013-08-12 |
2023-08-12 |
Not clear |
| Vivek Singh, Charles L Bowden, Jim Mint. Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania. International clinical psychopharmacology. vol 28. issue 2. 2013-07-12. PMID:23238761. |
forty patients with bipolar disorder i, currently in a mixed manic episode, were treated with adjunctive risperidone. |
2013-07-12 |
2023-08-12 |
Not clear |
| Dina Popovic, Maria Reinares, Jose Manuel Goikolea, Caterina Mar Bonnin, Ana Gonzalez-Pinto, Eduard Viet. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 5. 2013-01-22. PMID:22000157. |
the polarity index for the drugs used in maintenance therapy for bipolar disorder was 12.09 for risperidone, 4.38 for aripiprazole, 3.91 for ziprasidone, 2.98 for olanzapine, 1.39 for lithium, 1.14 for quetiapine, and 0.40 for lamotrigine. |
2013-01-22 |
2023-08-12 |
Not clear |
| Norris Turner, Wayne Macfadden, Ravi Anand, Sumant Khanna, Mark H Rapaport, J Thomas Haskins, Ibrahim Turkoz, Larry Alph. Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorder. Innovations in clinical neuroscience. vol 8. issue 10. 2013-01-09. PMID:22132367. |
this article describes the use of an independent, blinded relapse monitoring board to assess the primary outcome (relapse) in an international clinical trial of risperidone long-acting therapy adjunctive to standard-care pharmacotherapy for patients with bipolar disorder. |
2013-01-09 |
2023-08-12 |
Not clear |
| Basak Togar, Hasan Turkez, Abdulgani Tatar, Ismet Kirkpinar, Ahmet Hacimuftuoglu, Fatime Geyikoglu, M Sait Keles, Ebubekir Dirica. The genotoxic potentials of some atypical antipsychotic drugs on human lymphocytes. Toxicology and industrial health. vol 28. issue 4. 2012-10-17. PMID:21937534. |
olanzapine (olz), risperidone (rpd) and quetiapine (qtp) are atypical antipsychotic drugs and are commonly used for the treatments of schizophrenia and bipolar disorders. |
2012-10-17 |
2023-08-12 |
human |
| Javad Mahmoudi-Gharaei, Zahra Shahrivar, Toktam Faghihi, Mohammad Reza Mohammadi, Mehdi Tehrani-Doost, Javad Alaghband-Rad, Padideh Ghael. Topiramate versus Valproate Sodium as Adjunctive Therapies to a Combination of Lithium and Risperidone for Adolescents with Bipolar I Disorder: Effects on Weight and Serum Lipid Profiles. Iranian journal of psychiatry. vol 7. issue 1. 2012-10-12. PMID:23056111. |
to compare the effects of topiramate versus valproate sodium as an add-on therapy to a combination of lithium and risperidone (li+ris) on body weight and serum lipid profile in children and adolescents with bipolar disorder. |
2012-10-12 |
2023-08-12 |
Not clear |
| William V Bobo, Richard A Epstein, Alan Lynch, Tynya D Patton, Nicholas A Bossaller, Richard C Shelto. A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder. Clinical neuropharmacology. vol 34. issue 6. 2012-08-20. PMID:22104634. |
a randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder. |
2012-08-20 |
2023-08-12 |
Not clear |
| William V Bobo, Richard A Epstein, Alan Lynch, Tynya D Patton, Nicholas A Bossaller, Richard C Shelto. A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder. Clinical neuropharmacology. vol 34. issue 6. 2012-08-20. PMID:22104634. |
to compare adjunctive long-acting injectable risperidone plus treatment as usual (rlai+tau) versus tau alone for relapse, rehospitalization, and urgent care events in patients with bipolar disorder in routine care settings. |
2012-08-20 |
2023-08-12 |
Not clear |
| Alexandre Duarte Gigante, Beny Lafer, Lakshmi N Yatha. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS drugs. vol 26. issue 5. 2012-08-10. PMID:22494448. |
further, there is currently little information on the metabolic changes (apart from bodyweight gain) that may occur with the use of depot risperidone in patients with bipolar disorder, and this issue needs further investigation. |
2012-08-10 |
2023-08-12 |
Not clear |
| Mani N Pavuluri, Alessandra M Passarotti, Jacklynn M Fitzgerald, Ezra Wegbreit, John A Sweene. Risperidone and divalproex differentially engage the fronto-striato-temporal circuitry in pediatric mania: a pharmacological functional magnetic resonance imaging study. Journal of the American Academy of Child and Adolescent Psychiatry. vol 51. issue 2. 2012-06-07. PMID:22265362. |
the current study examined the impact of risperidone and divalproex on affective and working memory circuitry in patients with pediatric bipolar disorder (pbd). |
2012-06-07 |
2023-08-12 |
Not clear |
| Amy E West, Sally M Weinstein, Christine I Celio, David Henry, Mani N Pavulur. Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. Journal of child and adolescent psychopharmacology. vol 21. issue 6. 2012-04-24. PMID:22136096. |
co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. |
2012-04-24 |
2023-08-12 |
Not clear |
| Wayne Macfadden, Caleb M Adler, Ibrahim Turkoz, John T Haskins, Norris Turner, Larry Alph. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC psychiatry. vol 11. 2012-04-03. PMID:22034906. |
adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. |
2012-04-03 |
2023-08-12 |
human |
| Wayne Macfadden, Caleb M Adler, Ibrahim Turkoz, John T Haskins, Norris Turner, Larry Alph. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC psychiatry. vol 11. 2012-04-03. PMID:22034906. |
the objective of this exploratory analysis was to characterize efficacy and onset of action of a 3-month treatment period with risperidone long-acting injection (rlai), adjunctive to an individual's treatment regimen, in subjects with symptomatic bipolar disorder who relapsed frequently and had significant symptoms of mania and/or depression. |
2012-04-03 |
2023-08-12 |
human |
| Karen L Rascati, Kristin M Richards, Carol A Ott, Andrew W Goddard, Dana Stafkey-Mailey, Jose Alvir, Kafi N Sanders, Marko Mychaski. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatric services (Washington, D.C.). vol 62. issue 9. 2012-01-19. PMID:21885581. |
a retrospective study using medicaid claims identified patients with bipolar disorder for whom oral second-generation antipsychotics were prescribed and compared rates of adherence, persistence of use, and costs across five groups of patients taking aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone. |
2012-01-19 |
2023-08-12 |
Not clear |
| Susmita Chakraborty, Jayanta Chakraborty, Srikrishna Mandal, Malay Kumar Ghosa. A rare occurrence of isolated neutropenia with valproic acid: a case report. Journal of the Indian Medical Association. vol 109. issue 5. 2012-01-19. PMID:22187773. |
here in this study we report a case of a 28 year old female treated with valproic acid and risperidone for bipolar disorder, who developed isolated neutropenia within 6 months of commencement of therapy that got reversed soon after termination of valproic acid therapy. |
2012-01-19 |
2023-08-12 |
Not clear |
| William Victor Bobo, Stefania Bonaccorso, Karuna Jayathilake, Herbert Yale Meltze. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. Psychiatry research. vol 189. issue 2. 2011-11-08. PMID:21802150. |
prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. |
2011-11-08 |
2023-08-12 |
Not clear |